Celebrating the progression of treatment for Inherited Retinal Diseases on Rare Disease Day

Video

Dr Aleksandra Rachitskaya discusses how the treatment landscape for Inherited Retinal Diseases has changed and her hope for the future.

On Rare Disease Day, Dr Aleksandra Rachitskaya talks about how far treatment has come for Inherited Retinal Diseases. Once an untreatable diagnosis, Inherited Retinal Diseases now have an approved gene therapy option as well as more therapeutics under investigation.

Video transcript

Dr Rachitskaya: Hi, my name is Aleksandra Rachitskaya, and I'm a retina surgeon at Cleveland Clinic Cole Eye Institute. On this Rare Disease Day, I'm really excited about the future of Inherited Retinal Diseases. It used to be that Inherited Retinal Diseases were a type of diagnosis one was given, and there was not much hope in terms of treatment. A lot of patients would progressively lose vision and had to rely on low vision devices.

But these days, we do have an approved gene therapy, and also a lot of clinical trials focusing on gene therapy for a variety of Inherited Retinal Diseases. So on this Rare Disease Day, I think the future of Inherited Retinal Diseases as it comes to gene therapy is bright, and I'm excited to be part of that.

Note: This transcript has been lightly edited for clarity.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.